IP Library Granted Patent US 12691141
Granted Patent B2
US 12691141 · App. 17/924,336 · Granted Jul 28, 2026

Use of micro- and nano-MgH2 compound particles in inhibition of leishmania infection and treatment of leishmaniasis

Inventors: Guangyin Yuan (Shanghai, CN); Monica Echeverry Rendon (Shanghai, CN); Liang Jin (Shanghai, CN); Sara Maria Robledo Restrepo (Shanghai, CN)
Assignee: SHANGHAI JIAO TONG UNIVERSITY
A61K33/06A61K9/51A61P33/02B82Y5/00B82Y30/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12691141
App. No.
17/924,336
Granted
Jul 28, 2026
Kind
B2
Abstract

A use of micro- and nano-MgH 2 compound particles in the inhibition of Leishmania infection and in the treatment of Leishmaniasis is provided. The micro- and nano-MgH 2 compound particles can be used to prepare a pharmaceutical composition for inhibiting Leishmania or to prepare a pharmaceutical composition for treating a skin or mucosal ulcer or visceral damage caused by Leishmania infection. The present disclosure discovers for the first time that the micro- and nano-MgH 2 compound particles can significantly reduce the number of Leishmania in macrophages and inhibit the proliferation of Leishmania , indicating a very prominent insecticidal inhibition effect. The micro- and nano-MgH 2 compound particles of the present disclosure can quickly and effectively cure a skin ulcer and/or a mucosal ulcer caused by Leishmania and an impaired function of an internal organ (mainly liver and spleen) caused by Leishmania and have high biosafety and huge clinical application values.

Claims (3)

1 . A method of inhibiting Leishmania comprising a step of administering a pharmaceutical composition to a subject in need thereof, wherein the pharmaceutical composition comprises micro- and nano-MgH 2 compound particles and a pharmaceutically acceptable carrier and/or adjuvant; and an effective concentration of MgH 2 is 1 mg/100 uL to 15 mg/100 uL, wherein the micro- and nano-MgH 2 compound particles each have the particle diameter of 100 nm to 1,000 nm.

2 . A method of treating a skin or mucosal ulcer caused by a Leishmania infection comprising a step of administering a pharmaceutical composition to a subject in need thereof, wherein the pharmaceutical composition comprises micro- and nano-MgH 2 compound particles and a pharmaceutically acceptable carrier and/or adjuvant and an effective concentration of MgH 2 is 1 mg/100 uL to 15 mg/100 L wherein the micro- and nano-MgH 2 compound particles each have the particle diameter of 100 nm to 1,000 nm.

3 . A method of treating a visceral damage caused by a Leishmania infection comprising a step of administering a pharmaceutical composition to a subject in need thereof, wherein the pharmaceutical composition comprises micro- and nano-MgH 2 compound particles and a pharmaceutically acceptable carrier and/or adjuvant and an effective concentration of MgH 2 is 60 mg/kg to 500 mg/kg wherein the micro- and nano-MgH 2 compound particles each have the particle diameter of 100 nm to 1,000 nm.